Management of High-Cost and Complex Therapies
This webpage brings together ASHP’s resources on the management of high-cost and emerging therapies, addressing the unique challenges these treatments present for health systems. Explore strategies for stewardship, formulary management, cold chain requirements, and financial considerations to help pharmacy leaders optimize patient access and sustain system-wide readiness for these demanding therapies.
Reports & Toolkits
- PELA Virtual Conference Report: Strategic Directions in System Formulary, Drug Policy, and High-Cost Drug Management
- Toolkit for Evaluating Complex Medication Therapies and Creating Customized Scopes of Service Based on Medication Therapy Considerations
On-Demand Education
Publications
- Ultra-complex specialty medications: Meeting the challenges of significant medication requirements through an integrated specialty pharmacy model
- Pharmacy-directed coordination of gene and high-cost therapies
- Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025)
- Tackling the challenges of nanomedicines: are we ready?
ASHP and ASHP Foundation Pharmacy Forecast Reports
- 2025 report - Managing Ultra-High-Cost Drugs (pages 28-31)
- 2024 report - New Disease Paradigms and Treatment Innovations (pages 25-28)
Cold Chain Management
- Optimizing Pharmaceutical Cold Chain Management - Perspectives from Health-System Leaders
- ASHP Executive Forum on Cold Chain Management
- Resource Guide 1: Pharmaceutical Cold Chain Management in Health Systems
- Resource Guide 2: Health-Systems Design to Optimize Cold Chain Management
- Resource Guide 3: Preparing for the Future of Cold Chain Management
- ASHP Executive Forums on Cold Chain Management of Pharmaceuticals in Health Systems (AJHP)
- Cold chain management in health systems: Navigating a complex and evolving landscape (AJHP)
Podcasts
- High-Cost Medication Stewardship: Perspectives from Oncology Services
- Ultra-complex specialty medications: Meeting the challenges of significant medication requirements through an integrated specialty pharmacy model
Policy Positions
Please see the ASHP Policy Positions catalog to find the items below:
- 2307: Biosimilar Medications
- 1716: Greater Competition Among Generic and Biosimilar Manufacturers
- 2128: Use Of Unapproved Gene Therapy Products, Drugs, Biologics, And Medical Devices (Biohacking)
- 1821: Ensuring Effectiveness, Safety, And Access to Orphan Drug Products
- 1806: Manufacturer-sponsored Patient Assistance Programs
- 2013: Public Quality Standards for Biologic Products
- 2003: Anticancer Treatment Parity
ADVERTISEMENT